Business Standard

Saturday, February 15, 2025 | 12:23 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Dr Reddys Laboratories Ltd News

Infosys, ICICI Bank: 5 largecap stock ideas to trade amid market pullback

Technical charts show that shares of Infosys, ICICI Bank, Dr. Reddy's, Eicher Motors and Shriram Finance can potentially rally up to 15% from here on as Nifty attempts a pullback towards its 100-DMA.

Infosys, ICICI Bank: 5 largecap stock ideas to trade amid market pullback
Updated On : 06 Feb 2025 | 10:41 AM IST

Domestic funds' stake in this stock up over 2900% in FY25; check full list

DIIs have doubled their shareholding, in terms of absolute number of shares held, in 46 out of the Nifty 500 companies in the last nine months, shows ACE equity data.

Domestic funds' stake in this stock up over 2900% in FY25; check full list
Updated On : 30 Jan 2025 | 2:29 PM IST

Bajaj Finance, TaMo, Maruti: Largecap buy, sell stock ideas post Q3 results

Here's a technical outlook on 5 largecap stocks post Q3 results. Charts hint towards a positive bias for Bajaj Finance and Bajaj Auto; whereas a likely fall for Maruti, Tata Motors and Dr. Reddy's.

Bajaj Finance, TaMo, Maruti: Largecap buy, sell stock ideas post Q3 results
Updated On : 30 Jan 2025 | 11:17 AM IST

Dr Reddy's faces Revlimid cliff, analysts split on future growth prospects

Dr Reddy's Laboratories share price plunged 6.66 per cent at Rs 1,203.50 per share on the NSE in Friday's intraday deals after analysts remained cautious on the company's Q3 performance

Dr Reddy's faces Revlimid cliff, analysts split on future growth prospects
Updated On : 24 Jan 2025 | 9:58 AM IST

Stocks to Watch, Jan 24: ICICI Bank, Dr Reddy's, HPCL, Indus Towers, HFCL

Dr Reddy's Laboratories reported its consolidated Q3 results with a 2.5 per cent rise in profit to Rs 1,413.3 crore compared to Rs 1,378.9 crore in the same period last year

Stocks to Watch, Jan 24: ICICI Bank, Dr Reddy's, HPCL, Indus Towers, HFCL
Updated On : 24 Jan 2025 | 7:45 AM IST

'Optimistic' about Trump administration, says drugmaker Dr Reddy's

Earlier in the day, the generic drugmaker reported consolidated net profit of Rs 1,414 crore ($163.7 million) for the quarter ended Dec. 31

'Optimistic' about Trump administration, says drugmaker Dr Reddy's
Updated On : 23 Jan 2025 | 11:29 PM IST

Dr Reddy's Labs Q3 results: PAT rises 2.5% at Rs 1,413 cr, revenue up 16%

The growth was largely driven by revenue from its recently acquired nicotine replacement therapy (NRT) portfolio and performance in the European and emerging markets

Dr Reddy's Labs Q3 results: PAT rises 2.5% at Rs 1,413 cr, revenue up 16%
Updated On : 23 Jan 2025 | 8:39 PM IST

Dr Reddy's Lab Q3 results: Profit up 2.5% at Rs 1,413 cr, revenue rises 16%

Dr Reddy's Lab Q3 results: Shares of Dr Reddy's closed at Rs 1,289.35 on Thursday ahead of its results

Dr Reddy's Lab Q3 results: Profit up 2.5% at Rs 1,413 cr, revenue rises 16%
Updated On : 23 Jan 2025 | 5:24 PM IST

Q3 results today: Ultratech, HPCl, Zee among 59 to post earnings on Jan 23

Q3FY25 company results, January 23: Two Adani entities including Adani Energy Solutions and Adani Green Energy will release results for the Oct-Dec quarter today

Q3 results today: Ultratech, HPCl, Zee among 59 to post earnings on Jan 23
Updated On : 23 Jan 2025 | 9:20 AM IST

Dr Reddy's Labs Q3 Preview: Revlimid to dent US sales, profits may rise 12%

Indian pharmaceutical (IT) major, Dr Reddy's Laboratories, is scheduled to deliver its October-December quarterly earnings for the financial year 2024-25 (Q3FY25) on Thursday, January 23, 2025

Dr Reddy's Labs Q3 Preview: Revlimid to dent US sales, profits may rise 12%
Updated On : 20 Jan 2025 | 2:48 PM IST

Q3 results today: Zomato, Paytm, IDBI among 37 to post earnings on Jan 20

Q3 FY25 company results January 20: Zomato, Paytm, IDBI Bank, L&T Finance, Dr Reddy's, and YES Bank will be releasing their Oct-Dec quarter report today

Q3 results today: Zomato, Paytm, IDBI among 37 to post earnings on Jan 20
Updated On : 20 Jan 2025 | 9:42 AM IST

Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy' from 'Reduce'

Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit
Updated On : 08 Jan 2025 | 10:00 AM IST

Dr Reddy's up 15% in Dec so far; set for biggest monthly gain since Sep'20

Thus far in the month of December, Dr Reddy's share price has rallied 15%, its biggest monthly rally since September 2020, when it had surged 22%

Dr Reddy's up 15% in Dec so far; set for biggest monthly gain since Sep'20
Updated On : 27 Dec 2024 | 12:58 PM IST

Nifty Pharma index rallies 2% in weak market;Ipca, Dr Reddy's gain up to 6%

At 02:37 pm; Nifty Pharma, the sole gainer among sectoral indices, was up 1.8 per cent, as compared to 1 per cent decline in the Nifty 50.

Nifty Pharma index rallies 2% in weak market;Ipca, Dr Reddy's gain up to 6%
Updated On : 19 Dec 2024 | 3:21 PM IST

Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market

The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'

Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market
Updated On : 19 Dec 2024 | 12:07 PM IST

Kazakhstan authority imposes penalty of Rs 28.7 lakh on Dr Reddy's unit

Dr Reddy's Laboratories on Thursday said Kazakhstan revenue authority has levied a penalty of Rs 28.7 lakh on its subsidiary. The Department of State Revenue, Bostandyk district of Almaty, Kazakhstan has imposed the penalty on Dr Reddy's Laboratories Kazakhstan LLP towards disallowance of claim of certain expenses by the tax authorities for the calendar year 2021, the drug firm said in a regulatory filing. The order levies a penalty of KZT 17,597,212 (Rs 2.87 million), it added. "Based on our evaluation, there is no material impact on the financials, operations, or other activities of the company," the Hyderabad-based drug firm said.

Kazakhstan authority imposes penalty of Rs 28.7 lakh on Dr Reddy's unit
Updated On : 05 Dec 2024 | 6:47 PM IST

Dr. Reddy's up 2% on launching Toripalimab to treat nasopharyngeal cancer

In 2023, Dr. Reddy's entered into a license and commercialisation agreement with Shanghai Junshi Biosciences Co. Ltd for Toripalimab

Dr. Reddy's up 2% on launching Toripalimab to treat nasopharyngeal cancer
Updated On : 29 Nov 2024 | 9:46 AM IST

Dr Reddy's launches Toripalimab to treat nasopharyngeal cancer in India

In 2023, Dr Reddy's signed a licensing and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab

Dr Reddy's launches Toripalimab to treat nasopharyngeal cancer in India
Updated On : 28 Nov 2024 | 1:34 PM IST

Dr Reddy's Labs tanks over 3% after USFDA inspects Hyderabad API facility

Dr Reddy's Laboratories share price fell up to 3.2 per cent at Rs 1,175 per share on the BSE in Thursday's

Dr Reddy's Labs tanks over 3% after USFDA inspects Hyderabad API facility
Updated On : 21 Nov 2024 | 11:29 AM IST

USFDA issues seven observations to Dr Reddy's Hyderabad manufacturing plant

Dr Reddy's Laboratories Ltd on Tuesday said the US health regulator has issued a Form 483 with seven observations to its active pharmaceutical ingredient manufacturing facility in Bollaram, Hyderabad. "The US Food & Drug Administration (USFDA) today completed a GMP inspection at our API manufacturing facility (CTO-2) in Bollaram, Hyderabad," Dr Reddy's Laboratories Ltd (DRL) said in a regulatory filing. The inspection was conducted from November 13-19, 2024, it added. "We have been issued a Form 483 with seven observations, which we will address within the stipulated timeline," the company said. As per US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

USFDA issues seven observations to Dr Reddy's Hyderabad manufacturing plant
Updated On : 19 Nov 2024 | 7:39 PM IST